Trials / Completed

CompletedNCT01779492

A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 24 (actual)

Sponsor: GL Pharm Tech Corporation · Industry
Sex: Male
Age: 20 Years – 45 Years
Healthy volunteers: Accepted

Summary

The purpose of this clinical trial is to compare the pharmacokinetic characteristics of GL2907 XL 20mg tablet and Oxycontin CR 10mg tablet.

Detailed description

GL2907 XL 20mg tablet is controlled released formulation which is made by GL Pharm Tech.

Conditions

Healthy

Interventions

Type	Name	Description
DRUG	GL2907	once a day
DRUG	Oxycontine CR 10mg	twice a day

Timeline

Start date: 2013-04-01
Primary completion: 2013-06-01
Completion: 2013-08-01
First posted: 2013-01-30
Last updated: 2014-11-13

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01779492. Inclusion in this directory is not an endorsement.